Current Research Studies

Cancer – T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia

Condition or Therapy:

Acute Lymphoblastic Leukemia


Cancer and Blood Disorders
Study Number: T2012-002

What is the goal of this study?

The goals of this study are:

  • To evaluate the side effects (good and/or bad) of giving Marqibo® with other chemotherapy using the standard drugs dexamethasone, pegaspargase and mitoxantrone.
  • To evaluate the pharmacokinetics of Marqibo® when it is given with other chemotherapy agents
  • To measure how effective the combination Marqibo® with standard chemotherapy drugs is at treating children and young adults with relapsed ALL

Who can join the study?

This study may be a good fit for children and young adults who:

  • Between 1 and 21 years old at the time of study enrollment

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 2016-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Todd Cooper
Research Center: Center for Clinical and Translational Research